The Chinese and US patent authorities have both issued notices of allowance for a patent for the cod enzyme that is a key component for Enzymatica's cold spray ColdZyme®. The expected patents will be valid until 2036 in China and the USA respectively. The final grant in each country is expected during the autumn 2021 after finalization of the application process. The patents derive from the global patent application that was filed in 2015 and was granted for Europe in May 2020.

"The patents in China and the USA give ColdZyme® and other products based on the same technology platform a strong position in both markets. The two granted patents are important notices for Enzymatica's continued international expansion", said Claus Egstrand, Chief Operating Officer and incoming (January 2022) CEO at Enzymatica.

For more information, please contact:

Claus Egstrand, Chief Operating Officer, Enzymatica AB
Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com

Stefan Olsson, Communication Manager, Enzymatica AB
Phone: +46 (0)708 55 11 85 | Email: stefan.olsson@enzymatica.com

About Enzymatica AB

Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily

conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company's first product is the medical device ColdZyme®, a mouth spray against common cold. The product has been launched in about 30 markets on 3 continents. The strategy is to continue to grow by developing more health care products and strengthening the company's position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North Growth Market. For more information, visit: www.enzymatica.com and www.enzymatica.se/en/section/media/press-releases

Enzymatica's certified adviser is Erik Penser Bank.  Phone: +46 (0)8 463 83 00. Email: certifiedadviser@penser.se

Advisor on the patent portfolio is Potter Clarkson, one of Europe's leading patent firms.